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The aim of this report is to introduce an on-going,  multicenter,  randomized controlled trial to evaluate 
whether tailored antimicrobial prophylaxis guided by rectal culture screening prevents acute bacterial prostati-
tis following transrectal prostate biopsy (TRPB).  Patients will be randomized into an intervention or non-in-
tervention group; tazobactam-piperacillin or levofloxacin will be prophylactically administered according to the 
results of rectal culture prior to TRPB in the intervention group whereas levofloxacin will be routinely given in 
the non-intervention group.  The primary endpoint is the occurrence rate of acute bacterial prostatitis after 
TRPB.  Recruitment begins in April,  2021 and the target total sample size is 5,100 participants.
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T ransrectal prostate biopsy (TRPB) is an essential procedure to diagnose prostate cancer.  Although 
TRPB is usually preferred to transperineal biopsy from 
the standpoint of limiting post-operative pain and hos-
pitalization stays,  acute prostatitis after TRPB is a major 
concern.  Previous reports have noted that urinary tract 
infection after TRPB occurs in 0.1% to 7% of cases,  
some of which have been fatal [1 , 2].  The role of antibi-
otic prophylaxis to prevent infectious complications 
after TRPB is well established.  The American 
Urological Association (AUA),  European Association of 
Urology (EAU),  and Japanese Urological Association 
(JUA) support the use of prophylactic antibiotics before 
performing a TRPB [3-5].  Fluoroquinolones (FQs) 
remain the most common agents for TRPB antibiotic 
prophylaxis,  as recommended by worldwide guidelines.  
However,  increasing incidences of rectal colonization 
by FQ-resistant Escherichia coli (E. coli) and extended 
spectrum β-lactamase (ESBL)-producing E. coli have 
been reported;  these are the bacteria most commonly 
responsible for acute bacterial prostatitis after TRPB 
[5 , 6].
As acute bacterial prostatitis is caused by rectal flora,  
several reports have demonstrated that antibiotic pro-
phylaxis based on rectal swab cultures may be the most 
reasonable approach to reduce infections [7-9].  We 
previously reported that the use of selective media for 
detecting FQ-resistant and ESBL-producing pathogens 
from the rectum was a logical and rapid approach to 
prevent urinary infection after TRPB [7].  In addition,  
our results indicated that pre-TRPB screening of rectal 
flora using selective media could meaningfully guide 
prophylactic antibiotic treatment,  and potentially 
reduce acute bacterial prostatitis after TRPB [7].  
However,  a larger trial is necessary to evaluate the effi-
cacy of rectal culture screening using selective media to 
reduce acute bacterial prostatitis and sepsis after TRPB.  
The aim of this multicenter,  randomized controlled 
clinical trial is to investigate the usefulness of a tailored 
use of prophylactic antimicrobials according to results 
of screening for FQ-resistant or ESBL-producing E. coli 
colonies on selective media.
Endpoints
The primary endpoint in this trial is the incidence of 
acute bacterial prostatitis.  Prostatitis consists of pyuria 
and systemic symptoms such as a high fever over 38°C,  
urinary frequency/urgency,  and dysuria without evi-
dence of other infections.  Our diagnostic criteria do not 
include an elevated inflammatory response,  as evi-
denced by such measures as white blood cell (WBC),  
c-reactive protein (CRP),  and serum PSA levels,  bacte-
riological tests,  or imaging results.  Pyuria is defined 
as ≥ 10 WBCs/μL as determined by flow cytometric 
analysis,  ≥ 10 WBCs/mm3 as counted using a counting 
chamber,  a positive leucocyte esterase result from a 
urine test strip with uncentrifuged urine,  or > 5 WBCs/
high-power field (hpf) in the sediment of centrifuged 
urine.  The incidence of acute prostatitis will be com-
pared among the non-cultured,  positive-culture,  and 
negative-culture groups.
Secondary endpoints are the accuracy of the selec-
tive media and the severity at the onset of acute prosta-
titis.  The severity of prostatitis will be assessed using 
serum WBC,  CRP,  procalcitonin,  or a quick Sequential 
Organ Failure Assessment score (qSOFA).
Eligibility Criteria
In this study,  patients at participating facilities will 
be recruited starting April,  2021 and continuing for five 
years or until our target enrollment is met.  Adult 
(> 20 years old) male patients who schedule a transrec-
tal prostate biopsy with suspected prostate cancer 
during the period are eligible for enrollment.  All 
patients will be provided with written informed consent 
to participate in this study with full understanding.  
There are four exclusion criteria.  I:  Cases at high risk 
of infection,  defined as a prostate volume ≥ 75 mL,  dia-
betes mellitus,  systemic steroid use,  high-grade 
obstruction of the lower urinary tract (IPSS ≥ 20,  
Qmax ≤ 12 mL/s,  or residual urine ≥ 100 mL),  or an 
immunocompromised status;  in such cases two doses 
of PIPC/TAZ (pre- and post-operatively) are recom-
mended,  regardless of rectal culture results [10].  II:  
Transperineal prostate biopsy.  III:  Presence of pyuria 
at enrollment,  as pyuria indicates asymptomatic bacte-
riuria,  which increases the risk of postoperative acute 
bacterial prostatitis independent of rectal microbiota.  
IV:  A recent history of antibacterial medication,  as 
such would affect the results of rectal culture;  thus,  all 
patients receiving antibacterial medication less than 
four weeks before the rectal culture or prostate biopsy 
will be excluded.  
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Treatment Methods
This study is a multicenter,  open-label,  randomized 
controlled trial comparing the efficacy of tailored anti-
biotic prophylaxis based on rectal cultures using selec-
tive media versus standard levofloxacin prophylaxis to 
prevent acute prostatitis.  The trial will be conducted at 
16 sites in Japan (Table 1).  After eligibility is confirmed,  
participants will be randomized 1 : 1 to an intervention 
group or non-intervention group (rectal-culture group 
and non-rectal-culture group,  respectively) (Fig.1).  
Participants will be matched in pairs according to the 
institution of participant registration,  age,  prostate vol-
ume and history of antibacterial drug use for the past 6 
months.  Randomization will be conducted by the cen-
tral registration system at the office of the Japanese 
Research Group for Urinary Tract Infection (JRGU) 
located at the Department of Urology,  Hyogo College of 
Medicine.  Cases will be assigned based on a random 
assignment sheet prepared in advance.  Participant 
blinding is not possible due to the nature of the investi-
gation.
Selective screening media. We will use two kinds 
of CHROMagar Orientation media,  developed to detect 
FQ-resistant and ESBL-producing E. coli (Kanto 
Chemical,  Tokyo Japan),  respectively.  E. coli forms 
purple colonies on CHROMagar Orientation medium.  
Levofloxacin is added to the medium to detect 
FQ-resistant E. coli,  and CHROMagar Orientation/
ESBL is available to detect ESBL-producing E. coli 
[7 , 11].  Feces from the glove used for the rectal exam-
ination of patients with suspected prostate cancer will be 
applied to both selective screening media and incubated 
for 24 h before results are interpreted.
Protocol. Participants will be randomly divided 
into a rectal-culture group and non-rectal-culture group 
(Fig.1).  Patients in the rectal-culture group will be fur-
ther divided into a positive-culture and negative-culture 
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Table 1　 Participating medical institutions and doctors in charge
Institutions Investigators
　Fujita Health University Hospital,  Aichi Kiyohito Ishikawa
　Hakodate Goryoukaku Hospital,  Hokkaido Yoshiki Hiyama
　Hiroshima University Hospital,  Hiroshima Hiroyuki Kitano,  Jun Teishima
　Hyogo College of Medicine College Hospital,  Hyogo Shingo Yamamoto
　Internationla University of Health and Welfare Hospital,  Tochigi Jun Miyazaki,  Ei-Ichiro Takaoka
　Internationla University of Health and Welfare Narita Hospital,  Chiba Jun Miyazaki
　Japanese Red Cross Okayama Hospital,  Okayama Tadasu Takenaka
　Jikei University Katsushika Medical Center,  Tokyo Hiroki Yamada,  Hiroshi Kiyota
　Kobe University Hospital,  Hyogo Katsumi Shigemura,  Masato Fujisawa
　Kyoto University Hospital,  Kyoto Takayuki Goto
　Nagasaki University Hospital,  Nagasaki Tsubasa Kondo,  Yasuyoshi Miyata
　Okayama City General Medical Center,  Okayama Masaya Tsugawa
　Okayama Medical Center,  Okayama Takafumi Sakuma,  Norihiro Kusumi,  Takaharu Ichikawa
　Okayama Rosai Hospital,  Okayama Yoshitsugu Nasu
　Okayama University Hospital,  Okayama
Takuya Sadahira (Principal Investigator),  
Yuki Maruyama,  Kohei Edamura,  Takehiro Iwata,  
Motoo Araki, Masami Watanabe,  Toyohiko Watanabe,  
Yasutomo Nasu,  Koichiro Wada
　Sapporo Medical University Hospital,  Hokkaido Satoshi Takahashi,  Naoya Masumori
group,  depending on the results of their selective media 
cultures.  For the positive-culture group,  piperacillin/
tazobactam 4.5 g will be administered 30 min before 
the biopsy and 4 h after the biopsy [10].  For the nega-
tive-culture group,  one 500-mg dose of levofloxacin 
will be administered orally 2 h before the biopsy [12].  
Patients in the non-rectal-culture group will also 
receive 500 mg of levofloxacin orally 2 h before the 
biopsy.  After the biopsy,  there will be a one-month 
observation period to detect the incidence of acute bac-
terial prostatitis and its severity.  If there is evidence of 
acute prostatitis,  participants will be provided the 
appropriate treatment depending on the results of a uri-
nalysis,  urine culture,  and blood tests.
Statistical Consideration
Data management. In this trial,  data will be 
collected during the observation period by the local 
research staff.  Participating centers will send their case 
report forms as Excel files to the central research center 
(Okayama University),  where data entry into the data-
base will be completed and monitored by the central data 
manager.  Data on the case report form include:  institu-
tion of participant registration,  age,  body mass index,  
prostate volume,  history of antimicrobial exposure for 
the past 6 months,  preoperative prostate-specific anti-
gen level,  serum creatinine,  and the results of the rectal 
culture on selective media.  If patients develop prostati-
tis,  researchers will complete an additional data sheet.
Sample size calculation. The required sample 
size was calculated under the primary endpoint 
assumption that the pre-biopsy rectal culture reduces 
acute prostatitis from 2% to 1%,  with a statistical power 
of 80% and an alpha error of 5%.  Using a two-sided 
Fisher’s exact test,  it was calculated that 5,038 patients 
(2,519 per group) would be needed to detect a stan-
dardized difference between the rectal-culture and 
non-rectal-culture groups.  Assuming some attrition,  a 
sample size of 5,100 participants is thus required,  and 
the study will continue until that number is reached.  
Statistical analysis. Depending on data normal-
ity,  continuous data will be presented as either the 
means and standard deviations or medians and inter-
quartile intervals.  The statistical analysis will be per-
formed with either the Mann-Whitney U-test or 
Student’s t-test.  For categorical variables,  the data will 
be presented as counts and percentages then analyzed 
using Fisher’s exact test.  To confirm the efficacy of the 
rectal culture using selective media,  a univariate and 
multivariate logistic regression analysis will be per-
formed.  Statistical significance will be confirmed at 
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Fig. 1　 Trial protocol of the present study.
p < 0.05 for all analyses.  Statistical analyses will be per-
formed using JMP software (ver.  11;  SAS,  Cary,  NC,  
USA).
Ethics
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